KR20240082359A - 트라이아진 유도체를 함유하는 의약 조성물 - Google Patents

트라이아진 유도체를 함유하는 의약 조성물 Download PDF

Info

Publication number
KR20240082359A
KR20240082359A KR1020247013026A KR20247013026A KR20240082359A KR 20240082359 A KR20240082359 A KR 20240082359A KR 1020247013026 A KR1020247013026 A KR 1020247013026A KR 20247013026 A KR20247013026 A KR 20247013026A KR 20240082359 A KR20240082359 A KR 20240082359A
Authority
KR
South Korea
Prior art keywords
substituted
compound
group
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013026A
Other languages
English (en)
Korean (ko)
Inventor
유키 다치바나
쇼타 우에하라
유토 우노
겐지 나카하라
요시유키 다오다
고지 가사마쓰
유키코 야마쓰
시게루 안도
게이타 후카오
하루아키 노보리
다카유키 구로다
신스케 도바
겐타로 우에무라
유키 마루야마
미치히토 사사키
히로후미 사와
Original Assignee
시오노기 앤드 컴파니, 리미티드
국립대학법인 홋가이도 다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노기 앤드 컴파니, 리미티드, 국립대학법인 홋가이도 다이가쿠 filed Critical 시오노기 앤드 컴파니, 리미티드
Priority claimed from PCT/JP2022/035803 external-priority patent/WO2023054292A1/ja
Publication of KR20240082359A publication Critical patent/KR20240082359A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247013026A 2021-09-28 2022-09-27 트라이아진 유도체를 함유하는 의약 조성물 Pending KR20240082359A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JPJP-P-2021-157929 2021-09-28
JP2021157929 2021-09-28
JP2021171725 2021-10-20
JPJP-P-2021-171725 2021-10-20
JPJP-P-2022-000723 2022-01-05
JP2022000723 2022-01-05
JPJP-P-2022-015035 2022-02-02
JP2022015035 2022-02-02
JPJP-P-2022-131590 2022-08-22
JP2022131590 2022-08-22
PCT/JP2022/035803 WO2023054292A1 (ja) 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物

Publications (1)

Publication Number Publication Date
KR20240082359A true KR20240082359A (ko) 2024-06-10

Family

ID=85476839

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013026A Pending KR20240082359A (ko) 2021-09-28 2022-09-27 트라이아진 유도체를 함유하는 의약 조성물

Country Status (8)

Country Link
US (1) US20250127788A1 (https=)
EP (1) EP4410292A4 (https=)
JP (1) JP7236065B1 (https=)
KR (1) KR20240082359A (https=)
CN (1) CN119818502A (https=)
AU (1) AU2022353486A1 (https=)
CA (1) CA3233206A1 (https=)
MX (1) MX2024003600A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024193451A1 (en) * 2023-03-17 2024-09-26 Ascletis BioScience Co., Ltd Triazine derivatives, method of making and method of using thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092966A1 (ja) 2009-02-13 2010-08-19 塩野義製薬株式会社 新規トリアジン誘導体およびそれを含有する医薬組成物
WO2012020749A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
WO2013089212A1 (ja) 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物
WO2014200078A1 (ja) 2013-06-14 2014-12-18 塩野義製薬株式会社 アミノトリアジン誘導体およびそれらを含有する医薬組成物
WO2021205298A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and methods for the treatment of covid-19
WO2021250648A1 (en) 2020-09-03 2021-12-16 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036410A1 (en) * 1998-01-13 1999-07-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
EP4282420A4 (en) * 2021-01-20 2024-11-27 National University Corporation Hokkaido University ANTIVIRAL AGENT
EP4313097A4 (en) * 2021-03-29 2025-03-19 Shireen Nature Company for General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092966A1 (ja) 2009-02-13 2010-08-19 塩野義製薬株式会社 新規トリアジン誘導体およびそれを含有する医薬組成物
WO2012020749A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
WO2013089212A1 (ja) 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物
WO2014200078A1 (ja) 2013-06-14 2014-12-18 塩野義製薬株式会社 アミノトリアジン誘導体およびそれらを含有する医薬組成物
WO2021205298A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and methods for the treatment of covid-19
WO2021250648A1 (en) 2020-09-03 2021-12-16 Pfizer Inc. Nitrile-containing antiviral compounds

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study", [online], 2021년 11월 5일, Pfizer Press Release, [2022년 9월 21일 검색], 인터넷＜URL: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate＞
"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19", Journal of Virology, [online], 2021년 2월 23일, [2022년 9월 21일 검색], 인터넷<URL: https://jvi.asm.org/content/early/2021/02/19/JVI.01819-20><doi: 10.1128/JVI.01819-20>
"COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", [online], Johns Hopkins University, [2022년 9월 21일 검색], 인터넷<URL:https://coronavirus.jhu.edu/map.html>
"Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)", [online], 2020년 2월 28일, WHO, [2022년 9월 21일 검색], 인터넷<URL:https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>
261st Am Chem Soc (ACS) Natl Meet · 2021-04-05 / 2021-04-16 · Virtual, N/A · Abst 243
ACS Central Science(2021년), 7권, 3호, 467~475페이지
Arzneimittel-Forschung(1984년), 11권, 6호, 663~668페이지
Cancer Treatment Reviews(1984년), 11권, Supplement 1, 99~110페이지
Cell Research(2020년), 30권, 678~692페이지
Contributions to Oncology(1984년), 18권, 221~234페이지
Science(2003년), 300권, 1763~1767페이지
Science(2020년), 368권, 409~412페이지
Science(2021년), 374권, 1586~1593페이지
The NEW ENGLAND JOURNAL of MEDICINE(2020년), 382권, 1564~1567페이지

Also Published As

Publication number Publication date
CN119818502A (zh) 2025-04-15
JP7236065B1 (ja) 2023-03-09
MX2024003600A (es) 2024-04-09
CA3233206A1 (en) 2023-04-06
AU2022353486A1 (en) 2024-05-02
US20250127788A1 (en) 2025-04-24
EP4410292A4 (en) 2025-09-03
JPWO2023054292A1 (https=) 2023-04-06
EP4410292A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
TWI815396B (zh) 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物
JP7253866B1 (ja) トリアジン誘導体を含有する経口投与する製剤
WO2023054292A1 (ja) トリアジン誘導体を含有する医薬組成物
RU2612530C2 (ru) Производные бензимидазола, полезные при лечении респираторно-синцитиальной вирусной инфекции
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
WO2023042879A1 (ja) ウイルス増殖阻害活性を有する二環性複素環誘導体およびそれらを含有する医薬組成物
US20250025459A1 (en) Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
CN114787155B (zh) 药物化合物
KR20250004704A (ko) 바이러스 증식 저해 활성을 갖는 유라실 유도체 및 그들을 함유하는 의약 조성물
CN116514734A (zh) 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
JP2024178473A (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
KR20240137021A (ko) 신형 코로나바이러스 감염증 치료용 의약
CN116782904A (zh) 含有三嗪衍生物的医药组合物
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
HK40114521A (en) Pharmaceutical composition containing triazine derivative
AU2024307335A1 (en) Pharmaceutical composition containing uracil derivative
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
HK40081541B (zh) 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application